<DOC>
	<DOC>NCT00272480</DOC>
	<brief_summary>To determine whether the use of two antiviral agents in combination will be better than placebo in the treatment of an inflammatory sidease of the spinal cord caused by HTLV-I</brief_summary>
	<brief_title>Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial</brief_title>
	<detailed_description>Randomised, double-blind, placebo-controlled two centre study of zidvoudine plus lamivudine in HAM/TSP 24 patients randomised 1:1 2-4 week lead-in 6 months randomised phase followed by 6 months open-label therapy with active drug Primary endpoint: clinical Secondary endpoints: virological and immunological</detailed_description>
	<mesh_term>Spinal Cord Diseases</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Paraparesis, Tropical Spastic</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HTLVIassociated myelopathy prior exposure to zidovudine or lamvudine on disease modifying therapy under age 16</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>HAM/TSP</keyword>
	<keyword>HTLV-I-associated myelopathy</keyword>
	<keyword>zidovudine</keyword>
	<keyword>lamivudine</keyword>
	<keyword>antiretroviral therapy</keyword>
</DOC>